A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastati... by G.V. Long, R. Gutzmer, A. Haydon, E. Muñoz Couselo, C. Lebbé, M. Carlino, W. Chow, F. Couture, P. Lau, F. Spagnolo, A.J. Alves Wainstein, D. Palmieri, C. Rojas García, G. de Velasco Oria de Rueda, I. Mehmi, D. Patel, A. Shaikh, N.R. Chowdhury, S. Bathena, S. Suryawanshi, P. Rutkowski

Get full text

Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers by J. Palomero, V. Galvao, I. Creus, J. Lostes, M. Aylagas, A. Marín-Bayo, M. Rotxés, M. Sanz, M. Lozano-Rabella, A. Garcia-Garijo, A. Yuste-Estevanez, D. Grases, J. Díaz-Gómez, J. González, J.F. Navarro, J.J. Gartner, I. Braña, X. Villalobos, N. Bayó-Puxan, J. Jiménez, A.N. Palazón, S. Muñoz, G. Villacampa, A. Piris-Giménez, P. Barba, M. Codinach, L. Rodríguez, S. Querol, E. Muñoz-Couselo, J. Tabernero, S. Martín-Lluesma, A. Gros, E. Garralda

Get full text